Company: VCYT
Filing Date: 2025-06-18
Form Type: 8-K
Source: 0001384101-25-000083
Chunk: 0

Company: VERACYTE, INC.
Filing Date: 2025-06-18
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As further described in Item 5.07 to this Current Report on Form 8-K (this “ Report”), on June 17, 2025, at the 2025 Annual Meeting of Stockholders (the “ Annual Meeting”) of Veracyte, Inc. (the “ Company”), the Company’s stockholders approved an amendment to the Company’s 2023 Equity Incentive Plan (the “2023 Plan”) to increase the number of shares of the Company’s Common Stock, $0.001 par value, reserved for issuance under the 2023 Plan by 2,500,000 shares (the “2023 Plan Amendment”). The 2023 Plan Amendment had been approved, subject to stockholder approval, by the Company’s Board of Directors on April 14, 2025.

A more complete description of the 2023 Plan Amendment can be found in “ Proposal No. 5 - Approval of Amendment to Veracyte, Inc. 2023 Equity Incentive Plan” in the Company’s definitive proxy statement onSchedule 14A filed with the Securities and Exchange Commission on April 2 9, 202 5(the “ Proxy Statement”), which description is incorporated by reference herein. The foregoing description and the description incorporated by reference from the Proxy Statement are qualified in their entirety by reference to the 2023 Plan, as amended, a copy of which is filed as Exhibit 10.1 to this Report and is incorporated herein by reference.